Newsroom

January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.1 DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with AL amyloidosis.

Oct 19, 2020

NTLA-2001: First single-course therapy that potentially halts and reverses ATTR

On track to dose first patient by year-end with a systemically delivered CRISPR/Cas9-based therapy

Raymond Comenzo, MD, Tufts Medical Center, Boston, Massachusetts, discusses results from the ANDROMEDA trial, which showed superiority with the addition of daratumumab to CyBorD over CyBorD alone for patients with light chain (AL) amyloidosis. These results were presented during the virtual 2020 EHA Congress.

View the video here

This article is for people who have amyloidosis, or anyone who wants to learn more about this disease. The goal of this patient education activity is to inform you about amyloidosis, so that you can take a proactive role in your treatment and care.

Click here to be directed to this patient education activity.